8 Best Gene-Editing Stocks to Buy

4. Beam Therapeutics Inc. (NASDAQ:BEAM)

Number of Hedge Fund Holders: 35 

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company focused on precision genetic medicines using base editing, a technology that allows for precise, single-letter changes to DNA without cutting the strands. The company aims to develop treatments for genetic disorders, hematological diseases, and cancers. Its unique base editing technology offers a more accurate, predictable approach compared to traditional CRISPR, potentially reducing risks associated with DNA breaks.

Beam Therapeutics Inc. (NASDAQ:BEAM) recently reached a key milestone by achieving its adult enrollment target in the BEACON Phase 1/2 clinical trial of BEAM-101 for sickle cell disease. The company also presented promising early results from this trial at the 66th American Society of Hematology Annual Meeting. Additionally, the corporation plans to release initial data from its Phase 1/2 study of BEAM-302 for Alpha-1 Antitrypsin Deficiency (AATD) in the first half of 2025, solidifying its position among the best gene editing stocks in the biotech sector.

Beam Therapeutics Inc. (NASDAQ:BEAM) ended 2024 with a solid cash position of $850.7 million, supporting ongoing research and trials. R&D expenses were $101.4 million for the fourth quarter, reflecting a decrease from the previous year, which may indicate greater efficiency in its operations. General and administrative expenses were $28.7 million for Q4. However, the business reported a net loss of $90.4 million for the quarter and $376.7 million for the year, which is typical for biotech companies in the clinical stage.

The company’s revenue from licenses and collaborations significantly dropped from $316.2 million in Q4 2023 to $30.1 million in Q4 2024. This decrease warrants further investigation, as it may affect the company’s future financial stability. Despite this, Beam Therapeutics Inc. (NASDAQ:BEAM) expects its current cash reserves will fund operations into 2027, giving the company ample time to advance its key programs.